Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CHRND | Q07001 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905208 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL29615733 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL401138 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL31375263 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7836790 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL3217337 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7480026 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7464746 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905236 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL905201 | 0.89 | CHRNA3 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | claimed |
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-9168250-B2 | Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2015-10-27 | — | — | US | claimed |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | UNIVERSITÉ DE NÎMES (FR) | 2013-10-17 | — | — | US | claimed |
| US-20090124592-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | CENTRE NAT DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-05-14 | — | — | US | claimed |
| EP-1434573-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | Omeros Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | claimed |
| EP-0663912-B1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000023062-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | claimed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | claimed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNA3 2020/4885 |
| US-20130274293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY | OPRL1, HTR4, OPRM1 | CHRNB2 390/4885CHRNA4 82/4885CHRNA3 143/4885 |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | BACE2, PSEN2, APP | CHRNB2 83/4885CHRNA4 488/4885CHRNA3 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.